These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2936908)

  • 21. Alternative therapy for elderly patients with breast cancer.
    von Rueden DG; Sessions SC
    Am Surg; 1994 Jan; 60(1):72-8. PubMed ID: 8273979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Breast cancer and hormone therapy].
    Izuo M
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2830-6. PubMed ID: 2959203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Local forms of the treatment of recurrent breast cancer].
    Ishida T; Izuo M
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1318-24. PubMed ID: 3382201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
    Wapnir IL; Anderson SJ; Mamounas EP; Geyer CE; Jeong JH; Tan-Chiu E; Fisher B; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2028-37. PubMed ID: 16648502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy in stage III breast cancer.
    Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
    Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Does primary tumor affect the prognosis in postmastectomy locoregional recurrence in breast carcinoma?].
    Willner J; Kiricuta IC; Kölbl O
    Strahlenther Onkol; 1995 Jan; 171(1):18-28. PubMed ID: 7839301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma.
    Lê MG; Arriagada R; Spielmann M; Guinebretière JM; Rochard F
    Cancer; 2002 Jun; 94(11):2813-20. PubMed ID: 12115367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognosis of patients with locally recurrent breast cancer.
    Voogd AC; van Tienhoven G
    Am J Surg; 2007 Jan; 193(1):138. PubMed ID: 17188110
    [No Abstract]   [Full Text] [Related]  

  • 31. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiation therapy plus tamoxifen versus tamoxifen alone after breast-conserving surgery in postmenopausal women with stage I breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Lee JH; Recht A
    J Clin Oncol; 2003 Jun; 21(12):2260-7. PubMed ID: 12805324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Endocrine therapy of breast cancer].
    Jonat W; Maass H
    Zentralbl Gynakol; 1987; 109(10):617-27. PubMed ID: 2956805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Necessity of adjuvant therapy after radical mastectomy based on a study of patients with negative nodes, who have recurrent breast cancer].
    Asagoe T; Yamoto H; Nemoto A; Shikata J; Aoki A; Nakayama R; Tashiro Y
    Gan No Rinsho; 1988 Jan; 34(1):41-4. PubMed ID: 3339848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Survival and factors related to the survival of recurrent breast cancer patients--a study with quantification theory].
    Murayama Y
    Gan No Rinsho; 1983 Apr; 29(4):A-20, 311-4. PubMed ID: 6687908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Histochemical and biochemical assays of estrogen receptors in breast cancer and significance of endocrine therapy].
    Tominaga T
    Gan No Rinsho; 1983 May; 29(6):628-31. PubMed ID: 6308307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Negative margin status improves local control in conservatively managed breast cancer patients.
    Obedian E; Haffty BG
    Cancer J Sci Am; 2000; 6(1):28-33. PubMed ID: 10696736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.